Ideally, tumor antigens selected for CD3 and CD28 TCE combinations should have non-overlapping expression patterns in healthy tissues, increasing tumor specificity and minimizing OTOT toxicity of the combination immunotherapy to maximize the therapeutic index. This evidence concerns the gene CD28 and neoplasm.